SCHEDULE: Orca Capital AG Reports 9.9% Stake in Phio Pharmaceuticals Corp.

Orca Capital AG discloses a 9.9% ownership stake in Phio Pharmaceuticals Corp. as of December 19, 2024.

Summary

• Orca Capital AG filed a Schedule 13G with the SEC on January 23, 2025, reporting their ownership in Phio Pharmaceuticals Corp.
• As of December 19, 2024, Orca Capital AG beneficially owns 514,965 shares of Phio Pharmaceuticals Corp.'s common stock, representing 9.9% of the class.
• Orca Capital AG has sole voting and dispositive power over these shares.
• Between December 19, 2024, and the filing date, Orca Capital AG engaged in multiple acquisitions and disposals of Phio Pharmaceuticals Corp.'s common stock.
• The reported ownership excludes shares issuable upon the exercise of certain warrants containing blocker provisions that limit exercise to maintain ownership below 4.9% or 9.9%.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• Orca Capital AG holds a significant ownership position in Phio Pharmaceuticals Corp.

Risks

• The warrant exercise is limited by blocker provisions to maintain ownership below specified thresholds.

Future Outlook

The document does not contain any specific forward-looking statements regarding Phio Pharmaceuticals Corp.'s future performance or Orca Capital AG's intentions.

Industry Context

Schedule 13G filings are standard practice for investors who acquire more than 5% ownership in a publicly traded company, providing transparency to the market.

Comparison to Industry Standards

• Similar filings are common among institutional investors and large shareholders in publicly traded companies.
• The 9.9% ownership stake is a significant but not controlling interest, which is typical for investment firms.
• Comparable companies that have been subject to similar filings include those with significant institutional ownership, such as Moderna or BioNTech.

Stakeholder Impact

• The disclosure of Orca Capital AG's ownership stake provides transparency to shareholders of Phio Pharmaceuticals Corp.

Key Dates

Keywords

Schedule 13G, Phio Pharmaceuticals Corp, Orca Capital AG, Beneficial Ownership, Common Stock, SEC Filing